Drug
Jnj-40411813 clinical trials
Also written JNJ-40411813.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
- JNJ-40411813
- 6
Studies by the year they started
9 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2010 | 6 |
| 2012 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · Janssen Research & Development, LLC (2) · Janssen Pharmaceutical K.K. (1)
Often tested with
Tested in the same studies.
Ketoconazole (1) · JNJ-42491293 (1)
Studies
Open first, then newest update. How each study uses jnj-40411813 is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in EpilepsyCompletedPhase 2Janssen Research & Development, LLCNCT04836559Written as JNJ-40411813
- A Study of JNJ-40411813 in Healthy Japanese Male ParticipantsCompletedPhase 1Janssen Pharmaceutical K.K.NCT04677530Written as JNJ-40411813
- A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety SymptomsCompletedPhase 2Janssen Research & Development, LLCNCT01582815Written as JNJ-40411813
- Ketamine Challenge Study With JNJ-40411813CompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01101659Written as JNJ-40411813
- A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male PatientsCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01951053Written as JNJ-40411813
- A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813CompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01932320Written as JNJ-40411813: Formulation A
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly PatientsCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01932333Written as JNJ-40411813 50 mg
- A Dose-Ranging Study of JNJ-40411813 in Healthy Male VolunteersCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01358006Written as JNJ-40411813
- A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult VolunteersCompletedPhase 1Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT01359852Written as [11C] JNJ-42491293 + JNJ-40411813
Given in every arm · 1 — jnj-40411813 is usual care beside what is tested
Codes
What other systems call jnj-40411813 · ClinicalTrials.gg INT000162
- Wikidata Q27895859JNJ-40411813One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27895859 | JNJ-40411813 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.